PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy

Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new way for the treatment of many types of malignancies, particularly advanced-stage cancers. Accumulating evidence suggests that as a molecular imaging modality, positron emission tomography/computed tomography (PET/C...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yuan, Wu, Caixia, Chen, Xueqi, Ma, Linlin, Zhang, Xi, Chen, Jinzhi, Liao, Xuhe, Liu, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630646/
https://www.ncbi.nlm.nih.gov/pubmed/36341331
http://dx.doi.org/10.3389/fimmu.2022.1049043
_version_ 1784823653451431936
author Gao, Yuan
Wu, Caixia
Chen, Xueqi
Ma, Linlin
Zhang, Xi
Chen, Jinzhi
Liao, Xuhe
Liu, Meng
author_facet Gao, Yuan
Wu, Caixia
Chen, Xueqi
Ma, Linlin
Zhang, Xi
Chen, Jinzhi
Liao, Xuhe
Liu, Meng
author_sort Gao, Yuan
collection PubMed
description Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new way for the treatment of many types of malignancies, particularly advanced-stage cancers. Accumulating evidence suggests that as a molecular imaging modality, positron emission tomography/computed tomography (PET/CT) can play a vital role in the management of ICIs therapy by using different molecular probes and metabolic parameters. In this review, we will provide a comprehensive overview of the clinical data to support the importance of (18)F-fluorodeoxyglucose PET/CT ((18)F-FDG PET/CT) imaging in the treatment of ICIs, including the evaluation of the tumor microenvironment, discovery of immune-related adverse events, evaluation of therapeutic efficacy, and prediction of therapeutic prognosis. We also discuss perspectives on the development direction of (18)F-FDG PET/CT imaging, with a particular emphasis on possible challenges in the future. In addition, we summarize the researches on novel PET molecular probes that are expected to potentially promote the precise application of ICIs.
format Online
Article
Text
id pubmed-9630646
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96306462022-11-04 PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy Gao, Yuan Wu, Caixia Chen, Xueqi Ma, Linlin Zhang, Xi Chen, Jinzhi Liao, Xuhe Liu, Meng Front Immunol Immunology Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new way for the treatment of many types of malignancies, particularly advanced-stage cancers. Accumulating evidence suggests that as a molecular imaging modality, positron emission tomography/computed tomography (PET/CT) can play a vital role in the management of ICIs therapy by using different molecular probes and metabolic parameters. In this review, we will provide a comprehensive overview of the clinical data to support the importance of (18)F-fluorodeoxyglucose PET/CT ((18)F-FDG PET/CT) imaging in the treatment of ICIs, including the evaluation of the tumor microenvironment, discovery of immune-related adverse events, evaluation of therapeutic efficacy, and prediction of therapeutic prognosis. We also discuss perspectives on the development direction of (18)F-FDG PET/CT imaging, with a particular emphasis on possible challenges in the future. In addition, we summarize the researches on novel PET molecular probes that are expected to potentially promote the precise application of ICIs. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9630646/ /pubmed/36341331 http://dx.doi.org/10.3389/fimmu.2022.1049043 Text en Copyright © 2022 Gao, Wu, Chen, Ma, Zhang, Chen, Liao and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gao, Yuan
Wu, Caixia
Chen, Xueqi
Ma, Linlin
Zhang, Xi
Chen, Jinzhi
Liao, Xuhe
Liu, Meng
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
title PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
title_full PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
title_fullStr PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
title_full_unstemmed PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
title_short PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
title_sort pet/ct molecular imaging in the era of immune-checkpoint inhibitors therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630646/
https://www.ncbi.nlm.nih.gov/pubmed/36341331
http://dx.doi.org/10.3389/fimmu.2022.1049043
work_keys_str_mv AT gaoyuan petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy
AT wucaixia petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy
AT chenxueqi petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy
AT malinlin petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy
AT zhangxi petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy
AT chenjinzhi petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy
AT liaoxuhe petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy
AT liumeng petctmolecularimagingintheeraofimmunecheckpointinhibitorstherapy

Ejemplares similares